Segment Information

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Segment Information

Segment Information

Mylan has two segments, “Generics” and “Specialty.” The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients (“API”). The Specialty segment engages mainly in the development and sale of branded specialty nebulized and injectable products.

The Company’s chief operating decision maker evaluates the performance of its segments based on total revenues and segment profitability. Segment profitability represents segment gross profit less direct research and development (“R&D”) expenses and direct SG&A expenses. Certain general and administrative and R&D expenses not allocated to the segments, net charges for litigation settlements, impairment charges and other expenses not directly attributable to the segments, are reported in Corporate/Other. Additionally, amortization of intangible assets and other purchase accounting related items, as well as any other significant special items, are included in Corporate/Other. Intersegment revenues are accounted for at current market values and are eliminated at the consolidated level. As a result of changes to the organization structure at the end of 2013, certain R&D and selling and marketing expenses that were previously a component of the Specialty segment profitability are included within the Generics segment profitability beginning in 2014. Items below the earnings from operations line on the Company’s Condensed Consolidated Statements of Operations are not presented by segment, since they are excluded from the measure of segment profitability. The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker.

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.

(In millions)	Generics Segment		Specialty Segment		Corporate / Other(1)			Consolidated
Three Months Ended September 30, 2014
Total revenues
Third party	$	1,616.9	$	467.1	$	—		$	2,084.0
Intersegment	1.1		2.9		(4.0		)	—
Total	$	1,618.0	$	470.0	$	(4.0	)	$	2,084.0
Segment profitability	$	511.8	$	279.2	$	(296.0	)	$	495.0
Nine Months Ended September 30, 2014
Total revenues
Third party	$	4,675.9	$	961.0	$	—		$	5,636.9
Intersegment	3.7		7.3		(11.0		)	—
Total	$	4,679.6	$	968.3	$	(11.0	)	$	5,636.9
Segment profitability	$	1,267.1	$	535.3	$	(842.3	)	$	960.1

Three Months Ended September 30, 2013
Total revenues
Third party	$	1,404.4	$	363.0	$	—		$	1,767.4
Intersegment	1.7		4.2		(5.9		)	—
Total	$	1,406.1	$	367.2	$	(5.9	)	$	1,767.4
Segment profitability	$	369.2	$	189.8	$	(219.2	)	$	339.8
Nine Months Ended September 30, 2013
Total revenues
Third party	$	4,275.4	$	825.2	$	—		$	5,100.6
Intersegment	4.2		18.0		(22.2		)	—
Total	$	4,279.6	$	843.2	$	(22.2	)	$	5,100.6
Segment profitability	$	1,173.5	$	387.4	$	(698.6	)	$	862.3

____________

⁽¹⁾  Includes certain corporate general and administrative and R&D expenses; net charges for litigation settlements; certain intercompany transactions, including eliminations; amortization of intangible assets and certain purchase accounting items; impairment charges; and other expenses not directly attributable to segments.